Study of povorcitinib for teens with hidradenitis suppurativa
Treatments studied
Part of Infections, Skin clinical trials.
This trial tests an oral medication called povorcitinib for adolescents aged 12–17 with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with standard treatments like antibiotics. It aims to see how well the drug works and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 to 17 years old
- You must weigh at least 66 pounds (30 kg)
- You must have had moderate to severe HS for at least 3 months
- You must have at least 5 painful bumps or abscesses on your body
- You must have tried or been unable to take at least one standard treatment like antibiotics or a biologic for HS
- You agree to use contraception if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who have already taken the study drug povorcitinib in a previous trial and found it helpful. It lets you continue receiving the treatment and allows doctors to keep tracking its long-term safety and effects.
This trial tests a new medication called CIT-013 for people with moderate to severe hidradenitis suppurativa (HS) who have not had enough relief from oral antibiotics. The goal is to see if this treatment can reduce painful bumps and abscesses.
This trial is testing an experimental tablet called LT-002-158 in adults with moderate to severe hidradenitis suppurativa (HS) that hasn't improved enough with standard treatments. The goal is to see if it's safe and helps reduce painful lumps and abscesses.
This trial tests an investigational medicine, SPY072, for adults with moderate to severe hidradenitis suppurativa (also known as HS), a skin condition that causes painful lumps and sores. If you join, you'll help see if this treatment is safe and effective.
This trial tests a new drug called NAV-240 for people with hidradenitis suppurativa (HS) who have not had success with antibiotics. The goal is to see if the drug can reduce the number of painful lumps and improve symptoms.
This trial tests a new medicine called SCT650C for people with moderate to severe hidradenitis suppurativa (HS). The goal is to see if it can reduce painful bumps and abscesses better than current treatments.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.